برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Mulpleta (lusutrombopag) Tablets Date of Approval: July 31, 2018 Company: Shionogi Inc. Treatment for: Thrombocytopenia Mulpleta (lusutrombopag) is a once-daily, orally administered, thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a medical or dental procedure. https://t.me/ppdprogram

➡️Krintafel (tafenoquine) Tablets Date of Approval: July 20, 2018 Company: GlaxoSmithKline Treatment for: Malaria Krintafel (tafenoquine) is an 8-aminoquinoline derivative antimalarial for the radical cure (prevention of relapse) of Plasmodium vivax malaria. https://t.me/ppdprogram

➡️Qbrexza (glycopyrronium) Cloth for Topical Use Date of Approval: June 28, 2018 Company: Dermira, Inc. Treatment for: Hyperhidrosis Qbrexza (glycopyrronium) is a topical anticholinergic contained in a single-use, pre-moistened, medicated cloth for the treatment of primary axillary hyperhidrosis (excessive underarm sweating) in adults and children 9 years of age and older. https://t.me/ppdprogram

➡️Zemdri (plazomicin) Injection Date of Approval: June 25, 2018 Company: Achaogen, Inc. Treatment for: Urinary Tract Infection Zemdri (plazomicin) is an aminoglycoside antibacterial for the treatment of complicated urinary tract infections. https://t.me/ppdprogram

➡️Nocdurna (desmopressin acetate) Sublingual Tablets Date of Approval: June 21, 2018 Company: Ferring Pharmaceuticals Inc. Treatment for: Nocturia Nocdurna (desmopressin acetate) is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults. https://t.me/ppdprogram

➡️Olumiant (baricitinib) Tablets Date of Approval: May 31, 2018 Company: Eli Lilly and Company and Incyte Corporation Treatment for: Rheumatoid Arthritis, COVID-19, Alopecia Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis, COVID-19, and alopecia areata. https://t.me/ppdprogram

➡️Consensi (amlodipine and celecoxib) Tablets Date of Approval: May 31, 2018 Company: Kitov Pharma Ltd. Treatment for: High Blood Pressure, Osteoarthritis Consensi (amlodipine and celecoxib) is a calcium channel blocker and nonsteroidal anti-inflammatory drug combination for the treatment of both hypertension and pain associated with osteoarthritis. https://t.me/ppdprogram

➡️Palynziq (pegvaliase-pqpz) Injection Date of Approval: May 24, 2018 Company: BioMarin Pharmaceutical Inc. Treatment for: Phenylketonuria Palynziq (pegvaliase-pqpz) is a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria. https://t.me/ppdprogram

➡️Lokelma (sodium zirconium cyclosilicate) for Oral Suspension Date of Approval: May 18, 2018 Company: AstraZeneca Treatment for: Hyperkalemia Lokelma (sodium zirconium cyclosilicate) is a potassium binder indicated for the treatment of hyperkalemia in adults. https://t.me/ppdprogram

➡️Lucemyra (lofexidine hydrochloride) Tablets Date of Approval: May 16, 2018 Company: US WorldMeds Treatment for: Opiate Withdrawal Lucemyra (lofexidine hydrochloride) is a selective alpha 2-adrenergic receptor agonist indicated for reducing the severity of withdrawal symptoms in patients experiencing opioid withdrawal. https://t.me/ppdprogram

➡️Plenvu (polyethylene glycol 3350 with electrolytes) for Oral Solution Date of Approval: May 4, 2018 Company: Salix Pharmaceuticals, Inc. Treatment for: Bowel Preparation Plenvu (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride) is a lower-volume, polyethylene glycol based osmotic laxative indicated for cleansing of the colon (bowel preparation) prior to colonoscopy. https://t.me/ppdprogram

➡️Akynzeo for Injection (fosnetupitant and palonosetron) Date of Approval: April 19, 2018 Company: Helsinn Treatment for: Nausea/Vomiting, Chemotherapy Induced Akynzeo for Injection (fosnetupitant and palonosetron) is a substance P/neurokinin-1 (NK-1) receptor antagonist and serotonin-3 (5-HT3) receptor antagonist combination indicated for use with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV). https://t.me/ppdprogram

➡️ZTlido (lidocaine) Patch - formerly Ztilido Date of Approval: February 28, 2018 Company: Scilex Pharmaceuticals, Inc. Treatment for: Postherpetic Neuralgia ZTlido (lidocaine topical system 1.8%) is a transdermal anesthetic formulation for the treatment of pain associated with postherpetic neuralgia. https://t.me/ppdprogram

➡️Firvanq (vancomycin hydrochloride) for Oral Solution Date of Approval: January 26, 2018 Company: CutisPharma Treatment for: Clostridium Difficile Associated Diarrhea; Enterocolitis Firvanq (vancomycin hydrochloride) is an oral solution formulation of an approved tricyclic glycopeptide antibiotic for the treatment of Clostridium difficile associated diarrhea and Staphylococcus aureus enterocolitis. https://t.me/ppdprogram

➡️Dayvigo (lemborexant) Tablets Date of Approval: December 20, 2019 Company: Eisai Co., Ltd. Treatment for: Insomnia Dayvigo (lemborexant) is dual orexin receptor antagonist (DORA) for the treatment of insomnia. https://t.me/ppdprogram

➡️Caplyta (lumateperone) Capsules Date of Approval: December 20, 2019 Company: Intra-Cellular Therapies, Inc. Treatment for: Schizophrenia, Bipolar Disorder Caplyta (lumateperone) is an atypical antipsychotic for the treatment of schizophrenia and bipolar depression. https://t.me/ppdprogram

➡️Arazlo (tazarotene) Lotion Date of Approval: December 18, 2019 Company: Bausch Health Companies Inc. Treatment for: Acne Arazlo (tazarotene) is a lotion formulation of the approved retinoid tazarotene for the topical treatment of acne vulgaris in patients 9 years of age and older. https://t.me/ppdprogram

➡️Nouress (cysteine hydrochloride) Injection Date of Approval: December 13, 2019 Company: Avadel Pharmaceuticals plc Treatment for: Total Parenteral Nutrition Nouress (cysteine hydrochloride) is a sulfur-containing amino acid indicated for use as an additive to amino acid solutions to meet nutritional requirements of neonates requiring total parenteral nutrition. https://t.me/ppdprogram

➡️Oxbryta (voxelotor) Tablets Date of Approval: November 25, 2019 Company: Global Blood Therapeutics, Inc. Treatment for: Anemia, Sickle Cell Oxbryta (voxelotor) is an oral, HbS (sickle hemoglobin) polymerization inhibitor for the treatment of patients with sickle cell disease (SCD). https://t.me/ppdprogram

➡️Xcopri (cenobamate) Tablets Date of Approval: November 21, 2019 Company: SK Life Science, Inc. Treatment for: Seizures Xcopri (cenobamate) is an antiepileptic drug for the treatment of partial-onset seizures in adult patients. https://t.me/ppdprogram